Tagrisso 80 mg EGFR-mutation-positive non-small-cell lung cancer (3rd-gen TKI).
Osimertinib
Brand reference: Tagrisso (AstraZeneca, India)
View medicine details Oral oncology product portfolio
Explore our cancer medicine portfolio.
Browse the complete current list by molecule or brand name. A catalogue source reference does not identify the dispensing pharmacy or country, and a listing does not confirm availability.
28 medicines listed
Tagrisso 80 mg 
Xbira 250 mg Metastatic prostate cancer (CYP17 inhibitor).
Abiraterone
Brand reference: Zytiga (Janssen, India)
View medicine details
BDenza 160 Advanced prostate cancer (androgen-receptor inhibitor).
Enzalutamide
Brand reference: Bdenza
View medicine details
Palnat 125 HR+/HER2- advanced breast cancer (CDK4/6 inhibitor).
Palbociclib
Brand reference: Palnat
View medicine details
Kryxana 200 HR+/HER2- advanced breast cancer (CDK4/6 inhibitor).
Ribociclib
Brand reference: Kryxana (Novartis, India)
View medicine details
Ibyra 150 BRCA-mutated ovarian, breast, pancreatic and prostate cancers (PARP inhibitor).
Olaparib
Brand reference: Bracanat
View medicine details
Lenalid 10 Multiple myeloma and certain haematological cancers.
Lenalidomide
Brand reference: Lenalid
View medicine details
Veenat 400 Chronic myeloid leukaemia and GIST (tyrosine kinase inhibitor).
Imatinib
Brand reference: Imatib
View medicine details
Capegard 500 Breast, colorectal and gastric cancers (oral chemotherapy).
Capecitabine
Brand reference: Capegard
View medicine details
Geftinat 250 EGFR-mutation-positive non-small-cell lung cancer (first-generation TKI).
Gefitinib
Brand reference: Geftinat
View medicine details
Pomalid 1 mg Multiple myeloma.
Pomalidomide
Brand reference: Pomide
View medicine details
Dasanat 20 Chronic myeloid leukaemia and Philadelphia-chromosome-positive acute lymphoblastic leukaemia.
Dasatinib
Brand reference: Dasanat
View medicine details
Temotero 20 Brain tumours, including selected gliomas.
Temozolomide
Brand reference: Temonat
View medicine details
Sutinat 25 Renal cell carcinoma, gastrointestinal stromal tumours and pancreatic neuroendocrine tumours.
Sunitinib malate
Brand reference: Sunitinib
View medicine details
Pazoci 200 Renal cell carcinoma and soft-tissue sarcoma.
Pazopanib hydrochloride
Brand reference: Pazopanib
View medicine details
Evermil 10 Selected breast, renal cell and neuroendocrine tumours.
Everolimus
Brand reference: Evermil
View medicine details
Ramiven 100 mg HR-positive, HER2-negative breast cancer.
Abemaciclib
Brand reference: Ramiven
View medicine details
Venclexta 100 mg Chronic lymphocytic leukaemia and acute myeloid leukaemia.
Venetoclax
Brand reference: Venetoclax
View medicine details
Ibrunat 140 Chronic lymphocytic leukaemia, mantle-cell lymphoma and related blood cancers.
Ibrutinib
Brand reference: Ibrutinib
View medicine details
Letroz Hormone-sensitive breast cancer.
Letrozole
Brand reference: Letrozole
View medicine details
Altraz Hormone-sensitive breast cancer.
Anastrozole
Brand reference: Anazol
View medicine details
Soranib 200 Renal cell, liver and thyroid cancers.
Sorafenib tosylate
Brand reference: Sorafenib
View medicine details
Lenvat 10 Thyroid cancer and selected renal cell or liver cancer regimens.
Lenvatinib mesylate
Brand reference: Lenvatinib
View medicine details
Erlonat 100 EGFR-positive non-small-cell lung cancer and selected pancreatic cancer treatment.
Erlotinib
Brand reference: Erlocip
View medicine details
Combinib 250 HER2-positive breast cancer.
Lapatinib ditosylate
Brand reference: Lapatinib
View medicine details
Tamodex 20 Breast cancer.
Tamoxifen citrate
Brand reference: Tamoxifen
View medicine details
Nublexa 40 Colorectal cancer, gastrointestinal stromal tumours and liver cancer.
Regorafenib
Brand reference: Regorafenib
View medicine details
Jakavi 20 Myelofibrosis and selected haematological conditions.
Ruxolitinib
Brand reference: Ruxolitinib
View medicine detailsNot sure which name to search?
The active ingredient is often printed in smaller type below the brand name. A caregiver can search either name.